India’s Jubilant To Expand In U.S. Generics Market
This article was originally published in PharmAsia News
Executive Summary
Jubilant Organosys of India plans to market 10 generic drugs a year in the U.S. and Europe as it expands its presence in the two markets. European regulators have cleared the firm's plant in Roorkee intended for the expansion; U.S. FDA approval is expected within the next six months. So far, none of Jubilant's filings for market approval is a first-to-file application that would give it 180 days of generic exclusivity. Jubilant currently markets nine generics in the U.S., producing them in a U.S. plant, and has five in the approval stage. (Click here for more
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.